Mets Day 1120 Second scientific trial scan signifies potent results

Mets Day 1120 Second scientific trial scan signifies potent results

Image source: http://www.odwyerpr.com/site_images/041415usglc.jpg

Yesterday I had my moment CT scan as part of the nivolumab clinical trial. This scan took vicinity after I had received six of the experimental infusions, or 12 weeks after I began the trial. The first scan showed that my targeted tumors had reduced in size by 50%. This scan showed that the tumors continued to shrink, although not at the same rate. Here's the key language from the neck scan:

Findings: Although more than likely as a consequence of model in slice selection and patient positioning, there is slight interval decrease in the dimensions of the left level three lymph node as demonstrated on image 569 of series 4, now measuring 1.4 x 0.eight cm (previously 1.5 x 1.1 cm). The left level 4 lymph node previously measuring 1.three x 0.9 cm currently measures 1.three x 0.7 cm. Other smaller lymph nodes are either unchanged or smaller compared to the prior examination in the bilateral neck. There is no new lymphadenopathy. No mass or pathologic fluid collection is identified in the neck.
The scans of the chest and abdomen found no new tumors. The supraclavicular node is now "subcentimeter" in size and is "stable." There is no evidence of pulmonary embolisms, either. So the bottom line is that, in the past six weeks, the two target tumors reduced in size by another 25%. Yay!
The only poor news is that, consistent with the neck scan, I am 82 years historical (the abdomen and chest scan had my age correctly noted). I emailed the clinical trial nurse and mentioned that she'd have to report accelerated neck aging as one of the side consequences of the study. Her response: "I love your attitude and experience of humor."

I'll go in next week for my seventh infusion, and can communicate with Dr. Hahn concerning the durability of the nivolumab therapy. As far as I can tell, there is no publicly released data regarding the durability of nivolumab on metastatic bladder cancer patients. Nivolumab was first examined on metastatic melanoma. A March 2014 report found that the effects were durable for two or more years, and that some patients had ongoing beneficial consequences even after stopping therapy. A September 2014 report on the use of nivolumab on metastatic renal cell carcinoma also found durable results, with the ultimate results going to folks who stayed on the drug. A November 2014 exercise-up report on metastatic melanoma patients receiving nivolumab showed ongoing durability, with a median exercise-up of fifty five months, which consistent with the report "is the longest exercise-up of an anti-PD-1 agent carried out to date." That report also mentioned that, of the the patients who had an entire response, more than 0.5 were affirming that entire response. And a April 9, 2015 review of immunotherapy trials published by the British Cancer Journal found that

The most extensive clinical experience with PD-1 antibodies has been obtained with both nivolumab and pembrolizumab, which have demonstrated highly durable response rates with proper toxicity in tremendous phase I studies involving patients with advanced melanoma, NSCLC, renal cell carcinoma (RCC) and Hodgkins illness . . . .
None of those reports were true to bladder cancer, nevertheless. Although there are a host of reports noting the incontrovertible reality that nivolumab is being examined on mets bladder cancer patients, I have not been able to locate any data on the durability on my variety of cancer. The ultimate I can do is to extrapolate from the data from other cancers. From what I've been able to gather, here are the conclusions that I am drawing:
1. Nivolumab is a nice immunotherapy agent on my metastatic bladder cancer.
2. I have had an objective response — true, measurable results — as a consequence of the nivolumab.
three. I am persevering with to see tumor shrinkage as a consequence of the nivolmab.
4. This last scan likely has positioned me in the category of a complete response, meaning that my metastatic tumors have reduced in size to under 1 cm in size on the short axis.
5. I still have measurable illness, nevertheless, so I not yet at NED (no evidence of illness).
6. I should continue with the nivolumab as long as possible, since that is what has provided the ultimate results to patients taking nivolumab for other cancers. So that means no trips away from Hopkins for more than two weeks. I can stay with that.

median exercise-up is fifty five months, which represents the longest exercise-up of an anti-PD-1 agent carried out to date, – See more at: http://www.ajmc.com/conferences/SMR2014/Nivolumab-Shows-Durable-Response-in-Heavily-Pre-treated-Patients-with-Advanced-Melanoma#sthash.RLZL9hR2.dpuf
median exercise-up is fifty five months, which represents the longest exercise-up of an anti-PD-1 agent carried out to date, – See more at: http://www.ajmc.com/conferences/SMR2014/Nivolumab-Shows-Durable-Response-in-Heavily-Pre-treated-Patients-with-Advanced-Melanoma#sthash.RLZL9hR2.dpuf
median exercise-up is fifty five months, which represents the longest exercise-up of an anti-PD-1 agent carried out to date, – See more at: http://www.ajmc.com/conferences/SMR2014/Nivolumab-Shows-Durable-Response-in-Heavily-Pre-treated-Patients-with-Advanced-Melanoma#sthash.RLZL9hR2.dpuf

Leave a Reply

Your email address will not be published. Required fields are marked *